RMD · Insider Trading
ResMed Inc.
Every open-market purchase and sale reported by RMD officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-26 | Michael J Rider | Global General Counsel | Sell | −400 | −$102.00K |
| 2026-10-08 | Michael J. Farrell | Chairman and CEO | MIXED | — | −$399.25K |
| 2026-10-01 | Michael J Rider | Global General Counsel | A | +3,230 | — |
| 2026-10-01 | Justin Leong | Chief Product Officer | A | +6,461 | — |
| 2026-10-01 | Aaron Bloomer | Chief Financial Officer | A | +9,072 | — |
| 2026-10-01 | Michael J. Farrell | Chairman and CEO | — | — | — |
| 2026-10-01 | Michael J. Farrell | Chairman and CEO | A | +13,547 | — |
| 2026-09-10 | Michael J. Farrell | Chairman and CEO | MIXED | — | −$379.81K |
| 2026-09-04 | Peter C Farrell | Director | Sell | −970 | −$227.69K |
| 2026-08-11 | Michael J. Farrell | Chairman and CEO | MIXED | — | −$296.21K |
| 2026-08-06 | Peter C Farrell | Director | Sell | −8,000 | −$1.80M |
| 2026-08-06 | Peter C Farrell | Director | Sell | −8,000 | −$1.80M |
| 2026-07-09 | Michael J. Farrell | Chairman and CEO | MIXED | — | −$360.39K |
| 2026-06-09 | Michael J. Farrell | Chairman and CEO | MIXED | — | −$237.68K |
| 2026-06-03 | Michael J Rider | Global General Counsel | F | −268 | −$51.21K |
| 2026-05-11 | Michael J. Farrell | Chairman and CEO | MIXED | — | −$306.85K |
| 2026-05-04 | Brett Sandercock | Chief Financial Officer | — | — | — |
| 2026-04-09 | Michael J. Farrell | Chairman and CEO | MIXED | — | −$395.10K |
| 2026-04-03 | Brett Sandercock | Chief Financial Officer | Sell | −1,000 | −$224.31K |
| 2026-04-02 | Peter C Farrell | Director | Sell | −2,000 | −$450.00K |
| 2026-03-11 | Michael J. Farrell | Chairman and CEO | MIXED | — | −$522.52K |
| 2026-03-05 | Peter C Farrell | Director | Sell | −2,000 | −$520.44K |
| 2026-03-03 | Brett Sandercock | Chief Financial Officer | Sell | −1,000 | −$254.30K |
| 2026-02-10 | Michael J. Farrell | Chairman and CEO | MIXED | — | −$636.05K |
| 2026-02-06 | Michael J Rider | Global General Counsel | Sell | −50 | −$13.00K |
| 2026-02-06 | Peter C Farrell | Director | Sell | −2,000 | −$502.62K |
| 2026-02-03 | Brett Sandercock | Chief Financial Officer | Sell | −1,000 | −$257.03K |
| 2026-01-09 | Peter C Farrell | Director | Sell | −2,000 | −$497.66K |
| 2026-01-08 | Michael J. Farrell | Chairman and CEO | MIXED | — | −$509.68K |
| 2026-01-05 | Michael J Rider | Global General Counsel | Sell | −50 | −$12.09K |
| 2026-01-05 | Brett Sandercock | Chief Financial Officer | Sell | −1,000 | −$241.75K |
| 2025-12-09 | Michael J. Farrell | Chairman and CEO | MIXED | — | −$524.41K |
| 2025-12-04 | Peter C Farrell | Director | Sell | −2,000 | −$502.94K |
| 2025-12-02 | Brett Sandercock | Chief Financial Officer | Sell | −1,000 | −$244.16K |
| 2025-12-02 | Michael J Rider | Global General Counsel | Sell | −50 | −$12.21K |
| 2025-11-26 | Nicole Mowad-Nassar | Director | A | — | — |
| 2025-11-26 | Jan De Witte | Director | Sell | −2,055 | −$524.02K |
| 2025-11-26 | Peter C Farrell | Director | A | — | — |
| 2025-11-26 | Michael J. Farrell | Chairman and CEO | A | — | — |
| 2025-11-24 | Peter C Farrell | Director | A | +536 | — |
| 2025-11-24 | Jan De Witte | Director | A | +1,073 | — |
| 2025-11-24 | Christopher DelOrefice | Director | A | +1,073 | — |
| 2025-11-24 | Michael J. Farrell | Chairman and CEO | MIXED | +6,254 | — |
| 2025-11-24 | Brett Sandercock | Chief Financial Officer | A | +2,710 | — |
| 2025-11-24 | Ronald R Taylor | Director | A | +1,073 | — |
| 2025-11-24 | Carol Burt | Director | A | +1,073 | — |
| 2025-11-24 | Karen Drexler | Director | A | +1,073 | — |
| 2025-11-24 | Harjit Gill | Director | A | +1,073 | — |
| 2025-11-24 | Desney Tan | Director | A | +1,073 | — |
| 2025-11-24 | Nicole Mowad-Nassar | Director | A | +536 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Michael J. Farrell | Chairman and CEO | 486,884 | $111.95M |
| Brett Sandercock | Chief Financial Officer | 83,495 | $19.20M |
| Peter C Farrell | Director | 51,803 | $11.91M |
| Justin Leong | Chief Product Officer | 35,489 | $8.16M |
| Ronald R Taylor | Director | 24,771 | $5.70M |
| Kaushik Ghoshal | Chief Commercial Officer, SaaS | 19,430 | $4.47M |
| Carol Burt | Director | 18,816 | $4.33M |
| Richard Sulpizio | Director | 17,796 | $4.09M |
| Michael J Rider | Global General Counsel | 12,318 | $2.83M |
| Harjit Gill | Director | 10,940 | $2.52M |
| Karen Drexler | Director | 10,602 | $2.44M |
| Aaron Bloomer | Chief Financial Officer | 9,072 | $2.09M |
| Desney Tan | Director | 6,002 | $1.38M |
| John Hernandez | Director | 5,118 | $1.18M |
| Jan De Witte | Director | 4,261 | $979.77K |
| Christopher DelOrefice | Director | 2,423 | $557.14K |
| Nicole Mowad-Nassar | Director | 777 | $178.66K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the RMD quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.